Paul Nee, MD
Infectious Disease · Danbury, CTNPI 1326051913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Smith+Nephew at 36.3% of the total.
Across 38 payments — averaging $36.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$501
- Organogenesis Inc.$270
- Kerecis Limited$162
- Shockwave Medical, Inc$110
- Molnlycke Health Care US, LLC$87
- Avita Medical Americas, LLC$44
- plus $208 from 8 others
Across 40 payments — averaging $20,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$463K
- AstraZeneca$319K
- Dompe Farmaceutici S.p.a.$23K
- Eli Lilly$11K
What the payments were for
- Food & beverage$1,381100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 12 | $501 |
| Organogenesis Inc. | 10 | $270 |
| Kerecis Limited | 3 | $162 |
| Shockwave Medical, Inc | 1 | $110 |
| Molnlycke Health Care US, LLC | 1 | $87 |
| Avita Medical Americas, LLC | 1 | $44 |
| Next Science LLC | 2 | $42 |
| Tactile Systems Technology Inc | 2 | $37 |
| Urgo Medical North America, LLC | 1 | $26 |
| KCI USA, Inc. | 1 | $23 |
| Solventum Corporation | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Convatec Inc. | 1 | $20 |
| Lifenet Health | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,381 in reported general payments places this provider in the 75th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 13 | $1,607 |
| Gentamicin Sulfate | 12 | $429 |
| Cefadroxil | 26 | $250 |
| Mupirocin | 15 | $90 |
| Levofloxacin | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Danbury
- Gary SchleiterDanbury$1K
- John StratidisDanbury$541
- Zane SaulStratford$513K
- Stephen ScholandMeriden$428K
- Onyema OgbuaguNew Haven$412K
- David RubinNorwalk$397K
- Steven SchnittmanWest Haven$363K
- Kalpana GuptaWest Haven$160K
- Frederick AlticeNew Haven$143K
- Paul AnthonyHartford$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.